Cogent Biosciences Inc. (COGT) Set for Bezuclastinib Launch, Awaiting FDA Approval

Cogent Biosciences Inc. (NASDAQ:COGT) is one of the best cancer stocks to invest in now. On February 17, CEO Andrew Robbins reiterated that Cogent Biosciences Inc. (NASDAQ:COGT) has started 2026 with tremendous momentum backed by multiple value-creating regulatory catalysts. Cogent Biosciences Inc. (COGT) Set for Bezuclastinib Launch, Awaiting FDA Approval ldutko/Shutterstock.com In January, the US Food and Drug Administration accepted the company’s PEAK New Drug Application for bezuclastinib in patient ...